During the event, Luisa presented the key role that VisMederi will play in the upcoming Phase 2b clinical study. The meeting provided a valuable opportunity for in-depth discussions and fruitful exchanges on study details with investigators and partners.
We would like to thank Osivax and ClinChoice for the kind invitation and for the continued collaboration.
